There are CBD products for aches, pains, stress, agitation, and other health issues, and many such products come in the form of supplements, topical applications, and vapes. Now, there may be another use for CBD – oral products.
Two companies, Impression Healthcare and Aximbiotech have recently partnered. The former is a in the oral development business, while the latter is a research firm. Together, the two are seeking to determine what effect CBD has on treating periodontitis. The two announced their partnership in a recent press release.
According to the press release, trials were conducted by Impression Healthcare Limited. During the trials, 40 people with gingivitis and gum disease used cannabis-based toothpaste and mouthwash three times a day for over 30 days.
AXIM® Biotech CEO John W. Huemoeller II stated in the press release
“As a mid-stage biotech company, we found it strategic and necessary to partner with larger organizations who are experts in their respective fields in order to bring AXIM products to a much larger worldwide audience. This clinical trial registration through Impression is a tangible example of this methodology working.” He added, “Navigating the various regulatory agencies around the world in order to conduct clinical research on our products is both time-consuming and costly. Partnering with companies like Impression allows for AXIM’s products to be researched on a much faster and more cost-effective basis. We are extremely excited to reveal what we hope to be successful results that only further AXIM’s value-proposition as a leader in pharmaceutical quality cannabinoid-based products.”
Impression CEO Joel Latham added to the press release that
“We are excited to have assembled highly qualified researchers for the world’s first trial for the use of cannabinoids in the treatment of Gingivitis and Gum Disease. We are confident that the quality of the trial will supply the requisite peer-reviewed data for unique product sales under the SAS and will further develop commercialization opportunities for our products in this field.”
CBD-based oral health products have the potential to influence the growth of an already booming industry. At this point, the industry is already projected to reach $22 billion by 2022. Of course, there are also challenges faced by CBD companies looking to release oral products. Of instance, to protect their products, they need to receive a patent from the U.S. Trademark and Patent Office. Such patents also need to be enforced. Then, there is also the question of whether the products would come under the purview of a regulatory authority because they would be used for dental treatment.